Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plaquenil in Mild to Moderate COVID-19
NCT04384380Completed
- Sponsor
- Taoyuan General Hospital
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by Taoyuan General Hospital. Primary endpoint: Time to negatively rRT-PCR assessments at 14 days. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04384380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384380.